接受静脉-静脉体外膜氧合治疗的急性呼吸衰竭患者的年龄与相关结局:体外生命支持组织登记分析
本研究为基于登记的队列研究,使用144个中心的个体患者数据,纳入2017至2022年接受VV-ECMO的成年(≥18岁)急性呼吸衰竭患者,主要终点为住院死亡率,次要终点为VV-ECMO启动后并发症复合终点,采用贝叶斯分析估计年龄与结局的关联。共纳入27811例患者,其中11533例(41.5%)住院期间死亡。以18-29岁为参照,各年龄段的住院死亡率比值比逐级升高,30-39岁OR 1.17(95%CrI 1.06-1.31),40-49岁OR 1.65(95%CrI 1.49-1.82),50-59岁OR 2.39(95%CrI 2.16-2.61),60-69岁OR 3.29(95%CrI 2.97-3.67),70-79岁OR 4.57(95%CrI 3.90-5.37),≥80岁OR 8.08(95%CrI 4.85-13.74)。年龄增长与VV-ECMO后并发症之间也发现类似结果。
要点
- 基于144个中心27811例接受VV-ECMO的成人急性呼吸衰竭患者,住院死亡率为41.5%(11533例)。
- 以18-29岁为参照,30-39岁住院死亡OR 1.17(95%CrI 1.06-1.31),40-49岁OR 1.65(95%CrI 1.49-1.82)。
- 50-59岁OR 2.39(95%CrI 2.16-2.61),60-69岁OR 3.29(95%CrI 2.97-3.67)。
- 70-79岁OR 4.57(95%CrI 3.90-5.37),≥80岁OR 8.08(95%CrI 4.85-13.74)。
- 年龄增长与VV-ECMO启动后并发症复合终点之间也发现类似关联。
适用人群与场景
- 2017至2022年接受VV-ECMO的成年患者(≥18岁),来自144个中心的登记数据。
研究设计与关键结果
- 研究类型为基于登记的队列研究,使用144个中心的个体患者数据,纳入2017至2022年接受VV-ECMO的成年(≥18岁)急性呼吸衰竭患者,共27811例,其中11533例(41.5%)住院期间死亡。
- 主要终点为住院死亡率;采用贝叶斯分析(弱信息先验),以18-29岁为参照,30-39岁OR 1.17(95%CrI 1.06-1.31),40-49岁OR 1.65(95%CrI 1.49-1.82),50-59岁OR 2.39(95%CrI 2.16-2.61),60-69岁OR 3.29(95%CrI 2.97-3.67),70-79岁OR 4.57(95%CrI 3.90-5.37),≥80岁OR 8.08(95%CrI 4.85-13.74),各年龄段均与住院死亡率升高独立相关。
- 次要终点为VV-ECMO启动后并发症复合终点,年龄增长与该复合终点之间也发现类似结果。
证据类型、等级与局限
- 证据类型:基于登记的队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在接受VV-ECMO治疗的急性呼吸衰竭患者中,年龄增长与较差结局显著相关,且这种关联早在30岁时即已显现。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Venovenous extracorporeal membrane oxygenation (VV-ECMO) can be used to support patients with refractory acute respiratory failure, though guidance on patient selection is lacking. While age is commonly utilized as a factor in establishing the potential VV-ECMO candidacy of these patients, little is known regarding its association with outcome. We studied the association between increasing patient age and outcomes among patients with acute respiratory failure receiving VV-ECMO.
METHODS: In this registry-based cohort study, we used individual patient data from 144 centres. We included adult patients (≥ 18 years of age) receiving VV-ECMO from 2017 to 2022. The primary outcome was hospital mortality. Secondary outcomes included a composite of complications following initiation of VV-ECMO. We conducted Bayesian analyses to estimate the association between chronological age and outcomes.
RESULTS: We included 27,811 patients receiving VV-ECMO. Of these, 11,533 (41.5%) died in hospital. For the analysis conducted using weakly informed priors, and as compared to the reference category of age 18-29, the age brackets of 30-39 (odds ratio [OR] 1.17, 95% credible interval [CrI] 1.06-1.31), 40-49 (OR 1.65, 95% CrI 1.49-1.82), 50-59 (OR 2.39, 95% CrI 2.16-2.61), 60-69 (OR 3.29, 95% CrI 2.97-3.67), 70-79 (OR 4.57, 95% CrI 3.90-5.37), and ≥ 80 (OR 8.08, 95% CrI 4.85-13.74) were independently associated with increasing hospital mortality. Similar results were found between increasing age and post-ECMO complications.
CONCLUSIONS: Among patients receiving VV-ECMO for acute respiratory failure, increasing age is significantly associated with poorer outcomes, and this association emerges as early as 30 years of age.
参考来源
- Fernando SM, Brodie D, Barbaro RP, et al. Age and associated outcomes among patients receiving venovenous extracorporeal membrane oxygenation for acute respiratory failure: analysis of the Extracorporeal Life Support Organization registry. Intensive Care Med. 2024. PMID: 38376515. doi:10.1007/s00134-024-07343-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。